GE Healthcare Life Sciences and Germfree to co-develop modular solution for gene therapy
GE Healthcare Life Sciences and Germfree announced collaboration to develop a fully-integrated, expandable manufacturing environment for emerging biotherapeutics, including gene therapy.
With the unprecedented increase of the cell and gene therapy market, demand is exceeding supply. Current market indicators predict a compound annual growth rate of more than 36% in the cell and gene therapy market during 2019–2025, according to a market report published by BIS Research. The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market.
The manufacturing solution will feature a Germfree modular bioprocessing environment based on GE Healthcare’s proprietary design and equipped with FlexFactory, GE Healthcare’s integrated single-use biomanufacturing platform. This will be the latest addition to GE Healthcare’s KUBio prefabricated manufacturing facility offering.
To date, four KUBio facilities and 63 FlexFactory platforms have been acquired by manufacturers of biopharmaceuticals.
